Cyclo Therapeutics to Participate in the 2021 Virtual Cyclodextrin Conference Hosted by CycloLab
October 06 2021 - 08:05AM
Business Wire
Sharon H. Hrynkow, PhD, Chief Scientific
Officer, Senior Vice President of Medical Affairs to participate in
a Moderated round-table discussion with academics and industrial
experts on October 11, 2021 at 4:30 PM (CET) / 10:30 AM (EST)
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or
the “Company”), a clinical stage biotechnology company dedicated to
developing life-changing medicines through science and innovation
for patients and families living with diseases, today announced it
will participate in the 2021 Virtual Cyclodextrin Conference hosted
by CycloLab, “Cyclodextrins as active ingredients in the 21st
century,” taking place on October 11, 2021.
The event will focus on the use of cyclodextrins as active
ingredients both from a therapeutic/industrial and chemistry point
of view. As part of the event, Sharon H. Hrynkow, PhD, Chief
Scientific Officer, Senior Vice President of Medical Affairs of
Cyclo Therapeutics will participate in an interactive, moderated
round-table discussion with several key opinion leaders in the
field and address the questions of the attendees. The panel
discussion will begin at 4:30 PM (CET) / 10:30 AM (EST).
Trappsol® Cyclo™ is Cyclo Therapeutics’ proprietary formulation
of hydroxypropyl beta cyclodextrin and in multiple clinical studies
has shown encouraging results to effectively manage the
transportation of cholesterol. Taking the place of the defective
NPC1 protein, Trappsol® Cyclo™, with its cyclic structure,
facilitates the transport of accumulated cholesterol out of
cellular lysosomes so it can be further processed and excreted out
of cells.
Trappsol® Cyclo™ is currently being evaluated in a global Phase
3 pivotal trial, “TransportNPC,” for the potential treatment of
Niemann-Pick Disease Type C1 (NPC), a rare, fatal and progressive
genetic disorder. By the end of 2021, Cyclo Therapeutics will
submit an IND to FDA for a Phase 2 trial with Trappsol® Cyclo™ in
Alzheimer’s disease, an irreversible, progressive neurological
disorder, in which cholesterol is also implicated as a risk
factor.
For more information and registration for the event, please
visit the conference website here.
About Cyclo Therapeutics
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology
company dedicated to developing life-changing medicines through
science and innovation for patients and families suffering from
disease. The Company’s Trappsol® Cyclo™, an orphan drug designated
product in the United States and Europe, is the subject of four
formal clinical trials for Niemann-Pick Disease Type C, a rare and
fatal genetic disease, (www.ClinicalTrials.gov NCT02939547,
NCT02912793, NCT03893071 and NCT04860960). The Company is planning
an early phase clinical trial using Trappsol® Cyclo™ intravenously
in Alzheimer’s Disease based on encouraging data from an Expanded
Access program for late-onset Alzheimer’s Disease (NCT03624842).
Additional indications for the active ingredient in Trappsol®
Cyclo™ are in development. For additional information, visit the
Company’s website: www.cyclotherapeutics.com.
Safe Harbor Statement
This press release contains “forward-looking statements” about
the company’s current expectations about future results,
performance, prospects and opportunities, including, without
limitation, statements regarding the satisfaction of closing
conditions relating to the offering and the anticipated use of
proceeds from the offering. Statements that are not historical
facts, such as “anticipates,” “believes” and “expects” or similar
expressions, are forward-looking statements. These statements are
subject to a number of risks, uncertainties and other factors that
could cause actual results in future periods to differ materially
from what is expressed in, or implied by, these statements. The
factors which may influence the company’s future performance
include the company’s ability to obtain additional capital to
expand operations as planned, success in achieving regulatory
approval for clinical protocols, enrollment of adequate numbers of
patients in clinical trials, unforeseen difficulties in showing
efficacy of the company’s biopharmaceutical products, success in
attracting additional customers and profitable contracts, and
regulatory risks associated with producing pharmaceutical grade and
food products. These and other risk factors are described from time
to time in the company’s filings with the Securities and Exchange
Commission, including, but not limited to, the company’s reports on
Forms 10-K and 10-Q. Unless required by law, the company assumes no
obligation to update or revise any forward-looking statements as a
result of new information or future events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211006005054/en/
JTC Team, LLC Jenene Thomas (833) 475-8247 CYTH@jtcir.com
Cyclo Therapeutics (NASDAQ:CYTH)
Historical Stock Chart
From Feb 2024 to Mar 2024
Cyclo Therapeutics (NASDAQ:CYTH)
Historical Stock Chart
From Mar 2023 to Mar 2024